|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||
| Net loss | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Changes in estimated constraint on profit-sharing amount | |||||
| Depreciation and amortization | |||||
| Amortization of intangible assets | |||||
| Amortization of premiums (accretion of discounts) on investments, net | |||||
| Noncash lease expense | |||||
| Change in fair value of equity investments | |||||
| Change in estimated fair value of contingent consideration | |||||
| Payment of contingent consideration in excess of acquisition date fair value | |||||
| Gain from a sublease termination | |||||
| Stock-based compensation | |||||
| Change in deferred income taxes | |||||
| In-process research and development impairment | |||||
| Non-cash restructuring, long-lived assets impairment and related charges | |||||
| Other non-cash items, net | |||||
| Changes in operating assets and liabilities: | |||||
| Receivable from collaboration | |||||
| Prepaid expenses and other current assets | |||||
| Other assets | |||||
| Accounts payable | |||||
| Accrued liabilities and other long-term liabilities | |||||
| Operating lease liabilities | |||||
| Deferred revenue | |||||
| Net cash used in operating activities | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||
| Proceeds from sale of property and equipment | |||||
| Proceeds from sale of equipment | |||||
| Purchases of long-lived assets | |||||
| Purchases of investments | |||||
| Maturities and sales of investments | |||||
| Net cash provided by investing activities | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||
| Proceeds from exercise of stock options | |||||
| Contributions from noncontrolling interest owners | |||||
| Increase in ownership interest in a subsidiary | |||||
| Proceeds from issuance of common stock in connection with a collaboration agreement | |||||
| Proceeds from issuance of common stock in connection with a grant agreement | |||||
| Payment of contingent consideration | |||||
| Proceeds from issuance of common stock under ESPP | |||||
| Other financing activities | |||||
| Net cash provided by financing activities | |||||
| Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents | |||||
| Cash, cash equivalents and restricted cash and cash equivalents at beginning of period | |||||
| Cash, cash equivalents and restricted cash and cash equivalents at end of period | |||||
| Net refund received (cash paid) for income tax | |||||
| NONCASH INVESTING AND FINANCING ACTIVITIES: | |||||
| Operating lease liabilities obtained in exchange of right-of-use asset | |||||
| RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS TO THE CONSOLIDATED BALANCE SHEETS: | |||||
| Cash and cash equivalents | |||||
| Restricted cash and cash equivalents, current | |||||
| Restricted cash and cash equivalents, noncurrent | |||||
Loading...